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Abstract
Background: One of the most efficient radiation protection methods to reduce the risk of adverse health
outcomes in case of accidental radioactive iodine release is the administration of potassium iodine (KI). Although KI
administration is recommended by WHO’s guidelines for iodine prophylaxis following nuclear accidents and is also
widely implemented in most national guidelines, the scientific evidence for the guidelines lacks as the guidelines
are mostly based on expert opinions and recommendations. Therefore, this study will provide evidence by
systematically reviewing the effects of KI administration in case of accidental radioactive iodine release on thyroid
cancer, hypothyroidism, and benign nodules.
Methods: We will apply standard systematic review methodology for the identification of eligible studies, data
extraction, assessment of risk of biases, heterogeneity, and data synthesis. The electronic database search will be
conducted in MEDLINE (via PubMed) and EMBASE, and covers three search blocks with terms related to the health
condition, intervention, and occurrence/location. We have no date or language restrictions, but restrictions to
humans only. We will include studies comparing the effects of KI administration on thyroid cancer, hypothyroidism,
and benign thyroid nodules in a population exposed to radioactive iodine release. The quality of the studies will be
graded. If feasible, a meta-analysis will be conducted.
Discussion: This proposed systematic review will update the existing WHO guideline from 1999. New evidence on
the efficacy of KI administration to reduce thyroid cancer, hypothyroidism, and benign thyroid nodules in the event
of an accidental release of radioactive iodine to the environment will provide the basis for an update of the WHO
guideline for iodine prophylaxis following nuclear accidents.
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Background
Description of the condition
Radioactive isotopes of iodine (I-131) are generated in
large amounts as a by-product of uranium fission, which
is primarily used in nuclear reactors for energy produc-
tion. In the event of a nuclear reactor accident and when
radioactive material is released to the atmosphere, I-131
may be incorporated into the human body through in-
halation or ingestion of contaminated food and milk [1].
When inhaled, about 10–30 % of the radioactive iodine
will primarily accumulate in the thyroid gland while the
remaining amount will be discharged from the body with
the urine [2]. As part of I-131’s decay process, beta-
radiation is emitted and affects the thyroid and its
surrounding tissue and may lead to adverse health out-
comes such as thyroid dysfunctions and thyroid cancer.
From the Life Span Study, there is evidence for the de-
velopment of benign and malignant thyroid nodules as a
result of external exposure to ionizing radiation among
the atomic bomb survivors (e.g., [3]). Following the
Chernobyl reactor accident, which involved a large release
of I-131 into the environment, significantly increased
numbers of thyroid cancer and thyroid dysfunction such
as hypothyroidism were observed in individuals from
highly contaminated regions in Ukraine and Belarus
[4–6]. In addition, children and adolescents have been
found at higher risk for developing thyroid diseases
compared to adults. This is due to their smaller thy-
roid gland, its development during childhood and
adolescence which leads to a five to tenfold increase
of committed thyroid dose, higher uptake of radioio-
dine, and higher sensitivity to radioiodine release of
the organs, tissues, and cells [7–9]. Further, it is sug-
gested that radiation exposure during the prenatal
phase is associated with an increased risk for thyroid
cancer [10], and I-131 transmission from mother to
infant during breastfeeding has been investigated as
an additional risk factor for infants to develop thyroid
cancer in later stages in life [11, 12]. In contrast, radi-
ation-induced thyroid cancer risk for adults is thought to
be very low and may be close to zero [13].
Description of the intervention and how it might work
The oral administration of potassium iodine (KI) is as-
sumed to be the most effective and preventive radiation
protection measure to reduce the risk of adverse health
outcomes for the exposed population in the event of an
accidental release of radioactive iodine [14, 15]. KI es-
sentially saturates the iodide transport mechanism of the
thyroid by inhibiting the intrathyroid organification of
iodide (acute Wolff-Chaikoff effect), by dilution and by
promoting excretion and thus, reducing the amount of
committed dose to the thyroid gland, its surrounding tis-
sue, and the body [16–18].
KI administration depends on the predicted exposure
levels to the thyroid of the defined population groups
(i.e., intervention/action levels). KI doses further vary to
account for the respective risks of vulnerable population
groups (newborn, children and adolescents, and preg-
nant and lactating women). The effective blocking of the
thyroid is achieved with a dose of 130–170 mg of potas-
sium iodine. Fractions of these quantities are to be used
in specific population groups (1 in adults, adolescents in
addition to pregnant and lactating women, if necessary;
1/2 in children; 1/4 in infants; 1/8 in newborn) [19, 20].
Although KI administration blocks the thyroid gland, it
does not provide complete protection from accumulat-
ing radioactive iodine. A single dose of KI approximately
blocks the thyroid between 24 and 36 h but the blocking
capacity decreases with increased time after administra-
tion [19, 21]. In the event of continuous release of I-131,
repeated administration may be required to ensure pro-
longed protection of the general population as the
protective effect of one KI dose decreases with time.
The Polish government initiated KI administration in
the Polish general population, in particular in children
and adolescents, in late April and early May 1986 as a
consequence of the reactor accident in Chernobyl and
the subsequent discharge of radioactive iodine to the
environment. Assessing the efficacy of the KI adminis-
tration, Nauman and Wolff [22] estimated a reduction in
committed thyroid dose between 40 and 62 % for those
children who were administered KI 1–4 days after the
start of exposure. With regard to the timing of the inter-
vention, a simulation study demonstrated higher pro-
tective KI efficacy when its administration is carried out
in early exposure stages (78.9 vs. 39.1 % with KI given
within 2 h or at 8 h after uptake of radioactive iodine,
respectively) [15]. It is notable that in Poland as a result
of the immediate thyroid-blocking measures imple-
mented within the first 4 days after the start of the
exposure, it was achieved that about 90 % of the children
under the age of 16 showed thyroid dose commitments
below the predicted mean maximal burden (<50 mSv) in
this risk group [22].
A recent systematic review further examined the
adverse side effects of KI administration to block the
thyroid [23]. The evidence gathered from the systematic
review suggested that even the administration of high
doses of KI did not result in serious adverse health out-
comes in the exposed population groups. Severe reac-
tions of clinical significance were rare and in particular
observed in individuals with pre-existing thyroid disor-
ders and iodine sensitivity. There was little data available
on age differences. The review results however suggested
that newborns and the elderly may experience more
adverse side effects after KI administration compared to
other age groups [23]. Overall, the evidence base was
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relatively weak because with the exception of the Polish
study by Nauman and Wolff [22], most studies on the
effects of KI were primarily set in the clinical context
and addressed exposure reduction as part of therapy
procedures.
Why it is important to do this review
Iodine thyroid blocking using potassium iodine (KI) is
regarded as the most effective radiation protection
measure in the event of an accidental release of radio-
active iodine to reduce the risk of adverse health out-
comes for exposed populations. KI administration is
endorsed by WHO’s guidelines for iodine prophylaxis
following nuclear accidents and is also widely imple-
mented in most national guidelines. To date, the current
guidelines are primarily based on expert knowledge and
opinion while the scientific base was not established and
reviewed systematically.
As part of the update of the existing WHO guideline
from 1999 [20], present WHO regulations for guidelines
development require a systematic review of the scientific
evidence in order to inform the updating process [24].
Thus, the present project aims to provide an up-to-date re-
view on the efficacy of KI administration to reduce adverse
health outcomes such as thyroid dysfunctions and thyroid
cancer for the general population in the event of an acci-
dental release of radioactive iodine to the environment.
Objectives
We aim to assess the effects of KI administration on thy-
roid cancer, hypothyroidism, and benign thyroid nodules
in a population exposed to radioiodine release.
In particular, it is necessary to assess whether specific
population groups (e.g., children and adolescents between
0 and 18 years of age, pregnant or lactating women) are
differentially affected by KI administration, and to identify
appropriate timing, and in circumstances of repeated/con-
tinuous exposure, whether repeated KI administration
may be warranted to reduce the accumulation of I-131 in
the thyroid gland in the exposed population.
Methods
Criteria for considering studies for this review
Types of studies
The review intends to cover a broad spectrum of re-
search questions that are not necessarily assessed in ran-
domized clinical trials (RCTs). Thus, non-randomized
studies will be included in the review. More specifically,








– Surveys, e.g., pharmacoepidemiological studies
Types of participants
Participants included in studies are either the general
population or workers. No further specification is feas-
ible. The literature search is limited to evidence from
studies in humans.
Types of interventions
The interventions to be evaluated arise from the objectives
as outlined above.
The following intervention is considered:
– Stable oral iodine/potassium iodine administration
in the general population exposed to external
ionizing radiation or radioactive iodine in the
environment.
Types of outcome measures
The review will include studies that report the following
outcome measures:
– Prevalence and incidence of radiation-induced
thyroid cancer,
– Prevalence and incidence of radiation-induced
hypothyroidism,
– Prevalence and incidence of radiation-induced
benign thyroid nodules, and
– Mortality from radiation-induced thyroid cancer
(hypothyroidism and benign thyroid nodules are not
considered to be associated with mortality).
Search methods for identification of studies
Electronic searches
We will search the following academic databases:
– MEDLINE (1946 to present)
– Excerpta Medica Database (EMBASE) (1947 to
present)
We will apply a search strategy with additional keywords
for possible comparators and we will not use filters for
study types to improve the results of the literature search
with respect to the total number of relevant studies.
The databases as listed above will be searched until 16
June 2015.
For details on the MEDLINE and EMBASE search
strategies, see Additional files 1 and 2, respectively.
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Searching other resources
All relevant records for additional relevant studies will
be searched by hand.
Advisory group
We have established a review advisory group of experts
in the field of thyroid cancer, iodine thyroid blocking
and systematic reviews to further comment and provide
advice and suggestions to improve the manuscript in
protocol and review stages.
In protocol stage, Christoph Reiners, Rita Schneider
(UK Würzburg), Elie Akl (AUB, Beirut), Zhanat Carr, and
Susan Norris (both WHO) have provided feedback on the
research questions. Tomas Allen (WHO) has provided
feedback on the search strategy and the selected databases.
Vladimir Saenko (Nagasaki University) supported the
literature search.
Data collection and analysis
Selection of studies
A research librarian will assist the database search for
relevant studies. First, studies’ titles and abstracts, if
feasible, as identified by the search will be reviewed by
two authors independently. Second, both reviewers will
compare their list of relevant studies, and in case of any
disagreement, the opinion of a third author will be de-
cisive. Additionally, a third author screens the list of
relevant studies. Third, full texts of potentially relevant
studies will be retrieved or obtained. Fourth, the full
texts will be screened by the reviewers independently.
Fifth, each reviewer will create a list with studies that are
considered to fulfill the inclusion criteria. Sixth, the re-
viewers will compare their list with each other, and in
case of any disagreement, the opinion of a third author
will be decisive.
Based on these six steps, studies will be included for the
review. A flowchart based on the preferred reporting items
for systematic reviews and meta-analyses (PRISMA) will
be developed to visualize the selection of included studies.
Moreover, we will provide a table with statements on
excluded studies.
Data extraction and management
Data extraction will be performed by two authors inde-
pendently. In case of any disagreement, the opinion of a
third author will be decisive. We will use a modified data
extraction and assessment template from the Cochrane
Public Health Group (CPHG). Previous to the major
data extraction process, the authors will pilot the data
extraction form to ensure a standardized extraction. We
will extract general information (publication type, coun-
try of study, funding source of study, and potential
conflict of interest from funding), study eligibility (type
of study, participants, type of intervention, duration of
intervention, and type of outcome measures), and study
details (study intention, methods, results, intervention
group, outcomes, and other relevant information).
Data will be assembled and inserted into RevMan 5.3
by one author.
Assessment of risk of bias in included studies
The risk of bias of every included study will be evaluated
by two authors independently. In case of any disagree-
ment, the opinion of a third author will be decisive.
Based on the template provided from the CPHG, the
risk of bias will be assessed using the criteria for judging
risk of bias in Cochrane’s “Risk of bias” assessment tool
and the Cochrane Group’s Effective Practice and Organ-
isation of Care (EPOC) guidance for interrupted time
series (ITS) tool. Cochrane’s “Risk of bias” assessment
tool and the EPOC risk of bias tool for ITS examine the
following biases: selection, performance, detection, attri-
tion, reporting, and others. The EPOC risk of bias tool
for ITS examines three further risks of bias: “Was the
intervention independent of other changes?,” “Was the
shape of the intervention effect pre-specified?,” and
“Was the intervention unlikely to affect data collection?”
In the assessment of the risk of bias in cohort studies,
we will follow the best practice recommendation to assess
the specific features of cohort studies and the extent to
which these may introduce bias [25, 26]. At minimum, we
will assess the risk of bias in the following features: sam-
pling strategy, response rates, sample representativeness,
attrition, participant allocation, exposure assessment, out-
come assessment, and reporting and control of key
confounders and control of reverse causation.
To judge the risk of bias, the following categories will
be used: “no” (risk of bias is low), “yes” (risk of bias is
high), and “unclear” (information lacks or uncertainty
about the risk of bias) [27].
Measurement of treatment effect
Data synthesis aims to report changes in outcome mea-
sures from baseline to the post-intervention phase.
Dichotomous data will be expressed as odds ratios
(ORs), risk ratios (RRs), or risk differences (RDs). In ac-
cordance with the recommendations from the Cochrane
Public Health Group, RRs will be the preferred reported
data type. If RRs are not presented in the study, but data
to calculate the RRs are provided, we will calculate them.
If data to calculate the RRs are not provided, we will
contact the corresponding author of the study for the
RRs or the data to calculate the RRs by email or phone.
If we cannot provide RRs, we will use the data provided
in the study to report the treatment effect.
Continuous data will be expressed as standardized
mean differences (MDs). Shorter ordinal data will be
translated into dichotomous data (expressed as ORs,
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RRs, or RDs) and longer ordinal data will be treated as
continuous data (expressed as the standardized MDs).
Count data and Poisson data will be expressed as rate
ratios. Time-to-event data (survival data) will be trans-
lated into dichotomous data when appropriate or into
hazard ratios (HRs).
Unit of analysis issues
The analysis will consider the level at which randomization
occurred, e.g., cluster-randomized trials, cross-over trials,
and multiple observations (repeated observations on sub-
jects, recurring events, multiple body parts, and multiple
intervention groups) for the same outcome [27].
Dealing with missing data
We will contact study authors if relevant data is missing.
Data “not missing at random” due to publication bias,
systematic loss to follow-up, or systematic exclusion of
individuals from studies will be identified and requested
from study authors.
Assessment of heterogeneity
In the event of substantial clinical, methodological, or
statistical heterogeneity, we will not perform meta-
analytic pooling.
Heterogeneity will be detected through visual inspection
of the forest plots and by using a standard chi-squared test
with a significance level of P < 0.1 [27]. The I2 statistic will
be applied to quantify inconsistency across studies and to
assess the impact of heterogeneity on the meta-analysis
[27]. Potential reasons for heterogeneity will be examined
by conducting subgroup analyses.
Assessment of reporting bias
Reporting biases, including publication bias, time lag bias,
multiple (duplicate) publication bias, location bias, citation
bias, language bias, and outcome reporting bias, occur
when the dissemination of research results depends on
their magnitude and direction [27]. Study quality and risk
of bias of randomized controlled trials are assessed with the
Cochrane risk of bias tool [27]. Study quality and risk of
bias of non-randomized quantitative studies are assessed
with quality assessment tool for quantitative studies [28]. If
feasible, we will apply funnel plots for visual assessment for
study effects resulting from reporting biases. When testing
asymmetry in funnel plots (small study effects), we will in-
vestigate whether the size of the relation between a meas-
ure of study size and the estimated intervention effect is
larger than it is supposed to be [27]. RevMan 5.3 will be
used for the graphical representation of the funnel plots.
Data synthesis
If feasible, we will perform meta-analyses by applying
RevMan 5.3 for study results with clinical, methodological,
and statistical homogeneity. For dichotomous outcomes,
we will apply the Mantel-Haenszel method, and for con-
tinuous outcomes, we will apply the inverse variance
method. For all analyses, the random effects method will
be applied.
Study results with insufficient homogeneity will be
presented in a narrative synthesis.
We will provide a “Summary of findings” table [27].
This table includes information on the outcomes, illus-
trative comparative risks, the relative effect, the number
of participants, the number of studies included, the qual-
ity of evidence (GRADE), and additional comments.
GRADEprofiler will be used to prepare the “Summary of
findings” table.
Subgroup analysis and investigation of heterogeneity
We will investigate the following subgroups for primary
outcomes, where feasible:
– Children and adolescents (0–18 years) versus adults
– Males versus females
– Pregnant and lactating women versus other women
– Dosage of intervention (e.g., low or high)
– Timing of intervention (e.g., before, shortly after, or
long after exposure)
– Timing of exposure (e.g., one time, two or more
times, continuously)
– Magnitude of exposure (e.g., strong or weak)
– Repetition of intervention (e.g., after single, several,
or continuous exposures)
If feasible, we will apply t tests and chi-squared tests
to investigate statistical significance of between sub-
group differences in the treatment effect and we will
consider multiple test bias.
Sensitivity analysis
Sensitivity analyses will be performed to determine the
robustness of our results. To assess the impact of risk of
bias, we will conduct meta-analyses (if feasible):
– With studies considered as “low risk of bias” and
then compare results to those of studies considered
as “high risk of bias”
– With “large studies” and then compare the results to
those of “small studies”
– With published studies and then compare results to
those of unpublished studies
Discussion
We will perform a somewhat unusual review in a very spe-
cific research area to support the further development of a
WHO guideline on KI application in nuclear accidents with
population exposure to radioactive iodine. Although, there
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is much research on health consequences of radiation ex-
posure available, not much specific evidence on interven-
tion effects is anticipated, because of mostly unsystematic
application of KI in exposed populations so far, and result-
ing difficulties in researching potential effects at population
level. To get a clearer picture on the issue and support the
work of the guideline development group, we will aim to
derive evidence on the effectiveness of KI intake in sub-
groups, e.g., pregnant women. In addition, the dosage and
the timing of the intervention may be relevant for the ef-
fectiveness of KI on thyroid blockade. To our knowledge,
this will be the first systematic review that synthesizes infor-
mation on the effectiveness of KI administration to reduce
the risk of thyroid cancer, hypothyroidism, and benign nod-
ules in case of a nuclear accident.
Strengths and limitations
Our findings will depend on the quality and the number
of studies found. We focus on two large literature data-
bases and might thus not include studies that are not
included in these databases. However, from our research
prior to conducting the review and from consultation
with various experts on other potentially relevant data-
bases, this choice seems justified. Some studies might be
in Russian, Polish, or Japanese language. However, we
have experts from these countries assisting us in trans-
lating the content, extracting the data, and discussing
quality and other issues.
Review status
The authors have started searching relevant studies and
electronic databases. We expect the review to be com-
pleted by October 2015.
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